(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 1.47%
Live Chart Being Loaded With Signals
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 10 000.00 |
Vidutinė apimtis | 12 309.00 |
Rinkos kapitalizacija | 8.60M |
EPS | $0 ( 2024-03-13 ) |
Kita pelno data | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.30 |
ATR14 | $0 (0.00%) |
Crescita Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
FM.TO | 0.895 |
SKE.TO | 0.869 |
HOT-UN.TO | 0.859 |
CJR-B.TO | 0.855 |
GOOS.TO | 0.854 |
USA.TO | 0.849 |
TNT-UN.TO | 0.846 |
CRWN.TO | 0.844 |
ERO.TO | 0.837 |
JOY.TO | 0.831 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
HAC.TO | -0.879 |
SFC.TO | -0.869 |
E.TO | -0.858 |
THNC.TO | -0.844 |
CIA.TO | -0.827 |
SBB.TO | -0.825 |
EMP-A.TO | -0.824 |
SJ.TO | -0.814 |
RQN.TO | -0.813 |
ATE.TO | -0.809 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Crescita Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $17.52M |
Bruto pelnas: | $8.86M (50.55 %) |
EPS: | $-0.0980 |
FY | 2023 |
Pajamos: | $17.52M |
Bruto pelnas: | $8.86M (50.55 %) |
EPS: | $-0.0980 |
FY | 2022 |
Pajamos: | $23.53M |
Bruto pelnas: | $13.18M (56.03 %) |
EPS: | $0.0417 |
FY | 2021 |
Pajamos: | $16.77M |
Bruto pelnas: | $10.01M (59.72 %) |
EPS: | $-0.0500 |
Financial Reports:
No articles found.
Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.